The Federal Trade Commission announced on July 14, 2026 a settlement with Caremark, the pharmacy benefit manager owned by CVS Health, resolving the agency's antitrust case over insulin rebate practices. The deal locks in up to $8.5 billion in consumer savings over ten years, with up to $4.5 billion more in potential savings, and follows the FTC's earlier settlement with Express Scripts in February. Two of the industry's dominant middlemen have now agreed to restructure the rebate machinery that kept drug list prices high — a slow-moving change, but one aimed at the price you pay, not the price the system negotiates.
Why does the middleman decide your drug price?
Caremark does not make drugs or fill most prescriptions; it sits between employers, insurers, drugmakers and pharmacies, deciding which medicines get favored placement on formularies. The FTC's case alleged that rebate structures made high list prices profitable for the middleman: the larger the gap between a drug's list price and its post-rebate net price, the more value flowed through the negotiator. Patients, meanwhile, pay cost-sharing calculated from the list price. The settlement's changes aim to break that alignment — less reward for high-rebate drugs, more disclosure of where rebate money lands, and more of the negotiated value reaching patients at the counter.
Related stories: FTC settlement with Express Scripts targets insulin pricing · US store closings outpaced openings again in 2025.
Will you see lower prices at the pharmacy?
Over years, plausibly; this quarter, do not count on it. These are structural agreements measured in billions over a decade, and their effects arrive through formulary redesigns and benefit-year changes rather than through any single receipt. Your drug's position on your plan's tier list can shift at the next open enrollment as rebate rules change, which makes this the year to actually read the formulary documents instead of auto-renewing. If you take an expensive maintenance medication, reprice it at every renewal: the same molecule can move thousands of dollars a year between tiers.
What can you do at the counter right now?
Three checks beat waiting for structural reform. Ask the pharmacist for the cash price with a discount card before running insurance — on generics and older drugs, cash is frequently cheaper than the insured copay. Ask whether a therapeutic alternative sits on a better tier; formularies reward switching more than loyalty. And check whether your plan's pharmacy network includes the counter you use, because PBM-owned networks increasingly steer fills and a non-network pharmacy can cost you multiples of the copay you expected.
Why the pattern across both settlements matters
Express Scripts in February, Caremark in July: the FTC spent 2026 converting its insulin-pricing theory into binding consent orders covering the biggest names in the business. If the enforcement pattern continues, the rebate-driven incentive to inflate list prices weakens industry-wide, which is the only kind of drug-price cut that does not require you to find a coupon. Watch your copays at renewal — that is where the $8.5 billion will show up, if it shows up at all.
prices and policies change; check the retailer's current terms.